[1] Wong M,Huang J,George J,et al.The changing epidemiology of liver diseases in the Asia-Pacific region[J].Nat Rev Gastroenterol Hepatol,2019,16(1):57-73. [2] Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314. [3] Beste L A,Leipertz S L,Green P K,et al.Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans,2001-2013[J].Gastroenterology,2015,149(6):1471-1482,e17-e18. [4] Wu Y,Liu Z,Xu X.Molecular subtyping of hepatocellular carcinoma:A step toward precision medicine[J].Cancer Commun(Lond),2020,40(12):681-693. [5] Dominguez D A,Wang X W.Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma:How Precise Are We Really[J].J Hepatocell Carcinoma,2020,7:33-37. [6] Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314. [7] Nault J C,Galle P R,Marquardt J U.The role of molecular enrichment on future therapies in hepatocellular carcinoma[J].J Hepatol,2018,69(1):237-247. [8] El-Khoueiry A B,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(Check-Mate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502. [9] Zhu A X,Finn R S,Edeline J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-rando-mised,open-label phase 2 trial[J].Lancet Oncol,2018,19(7):940-952. [10] Finn R S,Ryoo B Y,Merle P,et al.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepa-tocellular Carcinoma in KEYNOTE-240:A Randomized,Double-Blind,Phase III Trial[J].J Clin Oncol,2020,38(3):193-202. [11] Kudo M.Targeted and immune therapies for hepa-tocellular carcinoma:Predictions for 2019 and beyond[J].World J Gastroenterol,2019,25(7):789-807. [12] Ramjiawan R R,Griffioen A W,Duda D G.Anti-angiogenesis for cancer revisited:Is there a role for combinations with immunotherapy[J].Angiogenesis,2017, 20(2):185-204. [13] Hegde P S,Wallin J J,Mancao C.Predictive markers of anti-VEGF and emerging role of angiogenesis inhi-bitors as immunotherapeutics[J].Semin Cancer Biol,2018,52(Pt 2):117-124. [14] Kudo M,Ueshima K,Yokosuka O,et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS):a ran-domised,open label,phase 3 trial[J].Lancet Gastroenterol Hepatol,2018,3(6):424-432. [15] Zimmermann M,Schulze-Hagen M,Pedersoli F,et al.Y90-radioembolization via variant hepatic arteries:Is there a relevant risk for non-target embolization[J].World J Radiol,2019,11(7):102-109. [16] Tsai C L,Liu W L,Hsu F M,et al.Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carci-noma cells in mice[J].Hepatology,2018,67(2):586-599.
2026, Vol. 46 
